Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study
(Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Australia Health | Children | Health | Pediatrics | Stem Cell Therapy | Stem Cells | Study